Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway

References

• Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017;8(2):256–265. doi:10.21037/jgo.2016.09.0728480065
   PubMed Web of Science ®Google Scholar
• Mathew S, Ali A, Abdel-Hafiz H, et al. Biomarkers for virus-induced hepatocellular carcinoma (HCC). Infect Genet Evol. 2014;26:327–339. doi:10.1016/j.meegid.2014.06.01424956436
   PubMed Web of Science ®Google Scholar
• Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract. 2017;71(11):e12972. doi:10.1111/ijcp.12972
   Web of Science ®Google Scholar
• Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808. doi:10.1016/j.jhep.2016.05.00727212245
   PubMed Web of Science ®Google Scholar
• Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep. 2017;50(3):117–125. doi:10.5483/bmbrep.2017.50.3.22227998397
   PubMed Web of Science ®Google Scholar
• Chiba T, Iwama A, Yokosuka O. Cancer stem cells in hepatocellular carcinoma: therapeutic implications based on stem cell biology. Hepatol Res. 2016;46(1):50–57. doi:10.1111/hepr.1254826123821
   PubMed Web of Science ®Google Scholar
• Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res. 2015;56(5):414–425. doi:10.3109/03008207.2015.106678026291921
   PubMed Web of Science ®Google Scholar
• Kharkar PS. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017;27(7):753–761. doi:10.1080/13543776.2017.132546528460551
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells and tumor metastasis (Review). Int J Oncol. 2014;44(6):1806–1812. doi:10.3892/ijo.2014.236224691919
   PubMed Web of Science ®Google Scholar
• Liu YC, Yeh CT, Lin KH. Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells. 2020;9:6. doi:10.3390/cells9061331
   Web of Science ®Google Scholar
• Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9(1):74. doi:10.1186/s13045-016-0307-927578206
   PubMed Web of Science ®Google Scholar
• Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. IL-6/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells. Onco Targets Ther. 2020;13:9721–9730. doi:10.2147/OTT.S26208933061451
   PubMed Web of Science ®Google Scholar
• Modi SJ, Kulkarni VM. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): reversal of TGF-beta induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. Eur J Med Chem. 2020;207:112851. doi:10.1016/j.ejmech.2020.11285133002846
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang J, Zhang X, Zhou H, Liu G, Li Q. Cancer stem cells: a potential Breakthrough in HCC-targeted therapy. Front Pharmacol. 2020;11:198. doi:10.3389/fphar.2020.0019832210805
   PubMed Web of Science ®Google Scholar
• Sampath TK, Reddi AH. Discovery of bone morphogenetic proteins - a historical perspective. Bone. 2020;140:115548. doi:10.1016/j.bone.2020.11554832730937
   PubMed Web of Science ®Google Scholar
• Herrera B, Sanchez A, Fabregat I. BMPS and liver: more questions than answers. Curr Pharm Des. 2012;18(27):4114–4125. doi:10.2174/13816121280243050322630083
   PubMed Web of Science ®Google Scholar
• Wang X, Wang JG, Geng YY, et al. An enhanced anti-tumor effect of apoptin-cecropin B on human hepatoma cells by using bacterial magnetic particle gene delivery system. Biochem Biophys Res Commun. 2018;496(2):719–725. doi:10.1016/j.bbrc.2018.01.10829355529
   PubMed Web of Science ®Google Scholar
• Garulli C, Kalogris C, Pietrella L, et al. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. Cell Signal. 2014;26(2):352–362. doi:10.1016/j.cellsig.2013.11.02224280125
   PubMed Web of Science ®Google Scholar
• Rampazzo E, Dettin M, Maule F, et al. A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation. Biochim Biophys Acta Gen Subj. 2017;1861(9):2282–2292. doi:10.1016/j.bbagen.2017.07.00128687190
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu P, Luo J, et al. LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling. EMBO J. 2019;38(17):e101110. doi:10.15252/embj.201810111031334575
   PubMed Web of Science ®Google Scholar
• Kanwal R, Shukla S, Walker E, Gupta S. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics. Cancer Lett. 2018;430:25–33. doi:10.1016/j.canlet.2018.05.01429775627
   PubMed Web of Science ®Google Scholar
• Feng PC, Ke XF, Kuang HL, Pan LL, Ye Q, Wu JB. BMP2 secretion from hepatocellular carcinoma cell HepG2 enhances angiogenesis and tumor growth in endothelial cells via activation of the MAPK/p38 signaling pathway. Stem Cell Res Ther. 2019;10(1):237. doi:10.1186/s13287-019-1301-231387619
   PubMed Web of Science ®Google Scholar
• Kim CJ, Terado T, Tambe Y, et al. Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness. Int J Oncol. 2018;52(1):231–240. doi:10.3892/ijo.2017.419429115414
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, Qu LH, Yang JH. Starbase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–7. doi:10.1093/nar/gkt124824297251
   PubMed Web of Science ®Google Scholar
• Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–8395. doi:10.1002/jcp.2774030417375
   PubMed Web of Science ®Google Scholar
• Sun L, Li PB, Yao YF, et al. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2018;24(10):1120–1133. doi:10.3748/wjg.v24.i10.112029563756
   PubMed Web of Science ®Google Scholar
• Wu W, Zhang X, Liao Y, et al. miR-30c negatively regulates the migration and invasion by targeting the immediate early response protein 2 in SMMC-7721 and HepG2 cells. Am J Cancer Res. 2015;5(4):1435–1446.26101708
   PubMed Web of Science ®Google Scholar
• Tanabe S, Quader S, Cabral H, Ono R. Interplay of EMT and CSC in cancer and the potential therapeutic strategies. Front Pharmacol. 2020;11:904. doi:10.3389/fphar.2020.0090432625096
   PubMed Web of Science ®Google Scholar
• Zhang F, Duan C, Yin S, Tian Y. MicroRNA-379-5p/YBX1 axis regulates cellular EMT to suppress migration and invasion of nasopharyngeal carcinoma cells. Cancer Manag Res. 2020;12:4335–4346. doi:10.2147/CMAR.S25350432606929
   PubMed Web of Science ®Google Scholar
• Erdogan S, Turkekul K. Neferine inhibits proliferation and migration of human prostate cancer stem cells through p38 MAPK/JNK activation. J Food Biochem. 2020;44(7):e13253. doi:10.1111/jfbc.1325332394497
   PubMed Web of Science ®Google Scholar
• Caruso S, O’Brien DR, Cleary SP, Roberts LR, Zucman-Rossi J. Genetics of HCC: novel approaches to explore molecular diversity. Hepatology. 2020. doi:10.1002/hep.31394
   Web of Science ®Google Scholar
• Pan Y, Ma S, Cao K, et al. Therapeutic approaches targeting cancer stem cells. J Cancer Res Ther. 2018;14(7):1469–1475. doi:10.4103/jcrt.JCRT_976_1730589025
   PubMed Web of Science ®Google Scholar
• Horne GA, Copland M. Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. Expert Opin Drug Discov. 2017;12(5):465–474. doi:10.1080/17460441.2017.130347728277836
   PubMed Web of Science ®Google Scholar
• Duan L, Ye L, Wu R, et al. Inactivation of the phosphatidylinositol 3-kinase/Akt pathway is involved in BMP9-mediated tumor-suppressive effects in gastric cancer cells. J Cell Biochem. 2015;116(6):1080–1089. doi:10.1002/jcb.2506325640278
   PubMed Web of Science ®Google Scholar
• Li CS, Tian H, Zou M, et al. Secreted phosphoprotein 24 kD (Spp24) inhibits growth of human pancreatic cancer cells caused by BMP-2. Biochem Biophys Res Commun. 2015;466(2):167–172. doi:10.1016/j.bbrc.2015.08.12426334966
   PubMed Web of Science ®Google Scholar
• Wang MH, Zhou XM, Zhang MY, et al. BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mTORC1 pathway. Aging (Albany NY). 2017;9(4):1326–1340. doi:10.18632/aging.10123028455969
   PubMedGoogle Scholar
• Feng Y, Jiang W, Zhao W, Lu Z, Gu Y, Dong Y. miR-124 regulates liver cancer stem cells expansion and sorafenib resistance. Exp Cell Res. 2020;394(2):112162. doi:10.1016/j.yexcr.2020.11216232640195
   PubMed Web of Science ®Google Scholar
• Yu H, Zhu X, Lin H, et al. A new risk model comprising genes highly correlated with CD133 identifies different tumor-immune microenvironment subtypes impacting prognosis in hepatocellular carcinoma. Aging (Albany NY). 2020;12(12):12234–12250. doi:10.18632/aging.10340932564007
   PubMedGoogle Scholar
• Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells. Cancers (Basel). 2017;9(9). doi:10.3390/cancers9090127
   PubMed Web of Science ®Google Scholar
• Zhao Z, Bai S, Wang R, et al. Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy. Cancer Manag Res. 2019;11:5737–5744. doi:10.2147/CMAR.S19763431296998
   PubMed Web of Science ®Google Scholar
• Kim BR, Oh SC, Lee DH, et al. BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. Tumour Biol. 2015;36(12):9475–9486. doi:10.1007/s13277-015-3681-y26124007
   PubMedGoogle Scholar
• Jing L, Ruan Z, Sun H, et al. Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol. 2019;234(10):18448–18458. doi:10.1002/jcp.2848030908631
   PubMed Web of Science ®Google Scholar
• Liu X, Fan D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr Pharm Des. 2015;21(10):1279–1291. doi:10.2174/138161282166614121111561125506898
   PubMed Web of Science ®Google Scholar
• Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39. doi:10.1002/1878-0261.1201728085222
   PubMed Web of Science ®Google Scholar
• Liang G, Fang X, Yang Y, Song Y. Silencing of CEMIP suppresses Wnt/beta-catenin/Snail signaling transduction and inhibits EMT program of colorectal cancer cells. Acta Histochem. 2018;120(1):56–63. doi:10.1016/j.acthis.2017.11.00229173982
   PubMed Web of Science ®Google Scholar
• Wei Y, Lv B, Xie J, et al. Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT. Drug Des Devel Ther. 2019;13:2343–2355. doi:10.2147/DDDT.S204787
   PubMed Web of Science ®Google Scholar
• Huang P, Chen A, He W, et al. BMP-2 induces EMT and breast cancer stemness through Rb and CD44. Cell Death Discov. 2017;3:17039. doi:10.1038/cddiscovery.2017.3928725489
   PubMed Web of Science ®Google Scholar
• Xiao S, Yang M, Yang H, Chang R, Fang F, Yang L. miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling. Oncogenesis. 2018;7(11):90. doi:10.1038/s41389-018-0097-830464168
   PubMed Web of Science ®Google Scholar
• da Cunha Jaeger M, Ghisleni EC, Cardoso PS, et al. HDAC and MAPK/ERK inhibitors cooperate To reduce viability and stemness in medulloblastoma. J Mol Neurosci. 2020;70(6):981–992. doi:10.1007/s12031-020-01505-y32056089
   PubMed Web of Science ®Google Scholar
• Huang B, Fu SJ, Fan WZ, et al. PKCepsilon inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P. Cancer Lett. 2016;376(1):148–154. doi:10.1016/j.canlet.2016.03.04127037060
   PubMed Web of Science ®Google Scholar
• Sun X, Xie Z, Ma Y, et al. TGF-beta inhibits osteogenesis by upregulating the expression of ubiquitin ligase SMURF1 via MAPK-ERK signaling. J Cell Physiol. 2018;233(1):596–606. doi:10.1002/jcp.2592028322449
   PubMed Web of Science ®Google Scholar
• Xie C, Zhu J, Wang X, et al. Tobacco smoke induced hepatic cancer stem cell-like properties through IL-33/p38 pathway. J Exp Clin Cancer Res. 2019;38(1):39. doi:10.1186/s13046-019-1052-z30691509
   PubMed Web of Science ®Google Scholar
• Tsai CF, Hsieh TH, Lee JN, et al. Curcumin suppresses phthalate-induced metastasis and the proportion of Cancer Stem Cell (CSC)-like cells via the inhibition of AhR/ERK/SK1 signaling in hepatocellular carcinoma. J Agric Food Chem. 2015;63(48):10388–10398. doi:10.1021/acs.jafc.5b0441526585812
   PubMed Web of Science ®Google Scholar